AMNEAL PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Amortization of Debt Issuance Costs of $9.20 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-03-01
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2020-12-31 was $3.68M, a 148.85% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2020-09-30 was $2.00M, a 0.00% change year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2020-06-30 was $1.00M, a 0.00% change year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for the quarter ending 2020-03-31 was $2.00M, a 0.00% change year-over-year.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2021 was $9.20M, a 6.05% increase from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2020 was $8.68M, a 33.96% increase from fiscal 2019.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2019 was $6.48M, a 10.56% increase from fiscal 2018.
- AMNEAL PHARMACEUTICALS, INC. amortization of debt issuance costs for fiscal 2018 was $5.86M, a 27.79% increase from fiscal 2017.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 3 month as first filed | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 6 month as first filed | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 9 month as first filed | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $9.20M 10-K · filed 2022-03-01 | ||||||
| 2020-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.68M derived: sum of 2 quarters · filed 2022-03-01 | $6.68M derived: sum of 3 quarters · filed 2022-03-01 | $8.68M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $2.00M 10-Q · filed 2020-11-06 | $3.00M derived: sum of 2 quarters · filed 2020-11-06 | $5.00M 10-Q · filed 2020-11-06 | $6.48M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $1.00M 10-Q · filed 2020-08-06 | $3.00M 10-Q · filed 2020-08-06 | $4.48M derived: sum of 3 quarters · filed 2022-03-01 | $6.48M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $2.00M 10-Q · filed 2020-05-11 | $3.48M derived: sum of 2 quarters · filed 2022-03-01 | $5.48M derived: sum of 3 quarters · filed 2022-03-01 | $6.48M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.48M derived: sum of 2 quarters · filed 2022-03-01 | $4.48M derived: sum of 3 quarters · filed 2022-03-01 | $6.48M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.00M 10-Q · filed 2020-11-06 | $3.00M derived: sum of 2 quarters · filed 2020-11-06 | $5.00M 10-Q · filed 2020-11-06 | $4.85M 10-Q · filed 2019-11-07 | $6.64M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $1.00M 10-Q · filed 2020-08-06 | $3.00M 10-Q · filed 2020-08-06 | $3.22M 10-Q · filed 2019-08-05 | $4.64M derived: sum of 3 quarters · filed 2021-03-01 | $6.24M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $2.00M 10-Q · filed 2020-05-11 | $1.60M 10-Q · filed 2019-05-09 | $3.64M derived: sum of 2 quarters · filed 2021-03-01 | $5.24M derived: sum of 3 quarters · filed 2021-03-01 | $6.64M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.24M derived: sum of 2 quarters · filed 2021-03-01 | $4.64M derived: sum of 3 quarters · filed 2021-03-01 | $5.86M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $1.60M 10-Q · filed 2018-11-07 | $3.00M derived: sum of 2 quarters · filed 2018-11-07 | $4.22M 10-Q · filed 2019-11-07 | $4.86M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $1.40M 10-Q · filed 2018-08-09 | $2.58M 10-Q · filed 2019-08-05 | $3.26M derived: sum of 3 quarters · filed 2020-03-02 | $4.66M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $1.17M 10-Q · filed 2019-05-09 | $1.86M derived: sum of 2 quarters · filed 2020-03-02 | $3.26M derived: sum of 3 quarters · filed 2020-03-02 | $4.76M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $690.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.09M derived: sum of 2 quarters · filed 2020-03-02 | $3.59M derived: sum of 3 quarters · filed 2020-03-02 | $4.58M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $1.40M 10-Q · filed 2018-11-07 | $2.90M derived: sum of 2 quarters · filed 2018-11-07 | $3.90M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | $1.50M 10-Q · filed 2018-08-09 | $2.46M 10-Q · filed 2018-08-09 | |||||
| 2016-12-31 | $3.06M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |